Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…
World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist (this article)
